Australia markets close in 2 hours 4 minutes

23andMe Holding Co. (ME)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.5000-0.1300 (-2.81%)
At close: 04:00PM EDT
4.5400 +0.04 (+0.89%)
After hours: 07:42PM EDT

23andMe Holding Co.

349 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 938 6300
https://www.23andme.com

Sector(s):Β Healthcare
Industry:Β Diagnostics & Research
Full-time employees:Β 

Key executives

NameTitlePayExercisedYear born
Ms. Anne WojcickiCo-Founder, CEO, Pres & Director59.28kN/AN/A
Mr. Steven J. SchochChief Financial and Accounting Officer582.15kN/A1959
Ms. Kathy L. Hibbs Esq., J.D.Chief Admin. Officer and Sec.567.2k340.28k1964
Dr. Kenneth J. Hillan Ch.B., M.B.Chief Therapeutics Officer582.2kN/A1961
Mr. Paul D. Johnson B.Sc.Chief Operating Officer of Consumer283.35kN/A1985
Dr. Joseph R. Arron M.D., Ph.D.Chief Scientific OfficerN/AN/AN/A
Dr. Wade WalkeVP of Investor RelationsN/AN/A1966
Ms. Jacquie Cooke Haggarty J.D.Gen. Counsel & Privacy OfficerN/AN/AN/A
Ms. Katie WatsonVP of CommunicationsN/AN/A1978
Mr. Mike PolcariVP & Chief ArchitectN/AN/A1981
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

Corporate governance

23andMe Holding Co.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.